An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

Share this content:
An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy (MARC-2)

Sponsors and Collaborators
iOMEDICO AG
Novartis

Contact
Luise Strassl
+49 (0)761 15242 ext 75
luise.strassl@iomedico.com

Principal Investigator
Michael Staehler, Dr. med, Ludwig-Maximilians-University Munich, Hospital Grosshadern

ClinicalTrials.gov Identifier
NCT01266837

You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters